22086-89-1

Usage

Uses

Used in Pharmaceutical Industry:
(2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID is used as a building block for the synthesis of various drugs and pharmaceutical compounds. Its versatile chemical structure allows for the development of new and innovative medications.
Used in Anti-inflammatory Applications:
(2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID is used as an anti-inflammatory agent due to its potential to modulate inflammatory pathways and reduce inflammation in the body.
Used in Analgesic Applications:
(2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID is used as an analgesic agent for its potential to alleviate pain and discomfort in various conditions.

InChI:InChI=1/C11H9NO3/c13-10(14)6-9-7-15-11(12-9)8-4-2-1-3-5-8/h1-5,7H,6H2,(H,13,14)/p-1

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 55-21-0 benzamide 
• 84446-03-7 ethyl 2-(2-phenyl-oxazol-4-yl)acetate 

Downstream Products

• 1334687-15-8 N,N-di-n-hexyl-2-(2-phenyl-1,3-oxazol-4-yl)acetamide 
• 1334687-12-5 2-(2-phenyl-1,3-oxazol-4-yl)-N,N-di-n-propylacetamide 
• 1334687-13-6 N,N-di-n-butyl-2-(2-phenyl-1,3-oxazol-4-yl)acetamide 
• 1334687-14-7 N,N-di-n-pentyl-2-(2-phenyl-1,3-oxazol-4-yl)acetamide 
• 201660-23-3 O-[4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenylmethyl]-N-triphenylmetyl-L-serine methyl ester 
• 201660-24-4 N-benzyloxycarbonyl-O-[4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenylmethyl]-L-serine methyl ester 
• 179170-38-8 4-[2-(2-Phenyl-4-oxazolyl)-ethoxy]phenylmethanol 
• 201660-22-2 4-[2-[4-(bromomethyl)phenoxy]ethyl]-2-phenyloxazole 
• 350810-76-3 2-phenyl-4-vinyloxazole 
• 179170-56-0 4-(2-(2-phenyl-4-oxazolyl)ethoxy)-benzaldehyde 
• 173173-54-1 2-(2-phenyloxazol-4-yl)-ethanol 

Relevant academic research and scientific papers

Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model

A number of 1,2,4-oxadiazol-5-yl-acetic acids and oxazol-4-yl-acetic acids were synthesized and tested for their ability to inhibit aldose reductase (ALR2). The oxadiazole derivatives, 7c, 7f, 7i, and 8h, 8i, proved to be the most active compounds, exhibiting inhibitory levels in the submicromolar range. In this series, the phenyl group turned out to be the preferred substitution pattern, as its lengthening to a benzyl moiety determined a general reduction of the inhibitory potency. The lead compound, 2-[3-(4-methoxyphenyl)-1,2,4- oxadiazol-5-yl]acetic acid, 7c, showed an excellent in vivo activity, proving to prevent cataract development in severely galactosemic rats when administered as an eye-drop solution in the precorneal region of the animals. Computational studies on the ALR2 inhibitors were performed to rationalize the structure-activity relationships observed and to provide the basis for further structure-guided design of novel ALR2 inhibitors.

Ramoplanin derivatives possessing antibacterial activity

Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

Synthesis of 2-phenyloxazole derivatives containing amino acids as insulin sensitivity enhancers for treatment of type II diabetes

The search for Insulin Sensitivity Enhancers (ISE) for use in the treatment of Non-Insulin Dependent Diabetes Mellitus (NIDDM) has led to the preparation of N-[(phenylmethoxy)carbonyl]-O-[[4-[2-(2-phenyl-4-oxazolyl)-ethoxy]phenyl] methyl]-L-serine (1) and 7-[2-(2-phenyl-4-oxazolyl)ethoxyl]-L-1,2,3,4-tetrahydro-N-Cbz- isoquinoline-3-carboxylic acid (2), that contain a 2-phenyloxazole moiety linked to an amino acid in place of the 2,4-thiazolidinedione pharmacophore. The 2-phenyloxazole was incorporated into 1 and 2 in high yield by alkylation of 4-hydroxybenzaldehyde or methyl 7-1,2,3,4-tetrahydro-N-benzyloxycarbonyl-hydroxyisoquinoline-3-carboxylate with 2-(2-phenyl-4-oxazolyl)ethyl p-toluenesulfonate (16). Successful incorporation of serine into 1 required use of an N-trityl protecting group to minimize β-elimination and epimerization at the α-center.